Main Article Content
Background There are variations in remission rates following treatment of steroid-resistant nephrotic syndrome (SRNS) with cyclophosphamide.
Objective To compare the efficacy of oral versus intravenous cyclophosphamide (CPA) in the management of pediatric SRNS.
Methods This was a prospective study of 41 children with SRNS treated with CPA. One group received oral CPA at a dose of 2 mg/kg body weight/day for 8-12 weeks, while the other group received intravenous CPA at a dose of 500mg/m2 body surface area (BSA) monthly for 6 months. All patients were concomitantly treated with prednisone on alternate days. The primary outcome was the number of patients attaining remission.
Results The study was comprised of 20 children receiving oral CPA and 21 children receiving intravenous CPA. There were 29 boys and 12 girls. The mean age of children at the onset of nephrotic syndrome (NS) was 47 ± 40 months old (range 12 months – 13 years), and the mean duration of NS before initiation of CPA therapy was 15 ± 28 months (range 1 – 129 months). Remission was achieved in 29 (70.7%) patients, with no difference between oral and intravenous route of CPA administration. The mean time to achieve remission was 22.7 weeks (about 5 months). The oral route group required less time in achieving remission than the intravenous route group. No association was found between remission and other factors, such as onset of steroid resistance, route of CPA, hypertension and hematuria. Side-effects included infection, anemia, nausea/vomiting, and alopecia. None of the patients required discontinuation of the medication.
Conclusion Oral CPA was as effective as intravenous CPA for children with steroid-resistant nephrotic syndrome. [Paediatr Indones. 2011;51:266-71].
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
2. Hodson EM, Wilis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database of Systematic Reviews. 2010;CD003594.
3. Del Rio M, Kaskel F. Evaluation and management of steroid-unresponsive nephrotic syndrome. Curr Opin Pediatr. 2008;20:151-6.
4. Bircan Z, Kara B. Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome. Pediatr Int. 2003;45:65-7.
5. Filler G. Treatment of nephrotic syndrome in children and controlled trials. Nephrol Dial Transplant. 2003;18[Suppl 6]:vi75-vi78.
6. Valeri A, Radhakrishnan J, Estes D, D’Agati V, Kopelman R, Pernis A, et al. Intravenous pulse cyclophosphamide treatment of lupus nephritis: a prospective five year study. Clin Nephrol. 1994;42:71-8.
7. Sümegi V, Haszon I, Bereczki C, Papp F, Türi S. Long-term follow-up after cyclophosphamide and cyclosporin-A therapy in steroid-dependent and –resistant nephrotic syndrome. Pediatr Nephrol 2008;23:1085-92.
8. Indian Society of Pediatric Nephrology. Management of steroid resistant nephrotic syndrome. Indian Pediatrics. 2009;46:35-47.
9. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, et al. Cyclosporine versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicenter randomized controlled trial. Nephrol Dial Transplant. 1993;8:1326–32.
10. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;62:629-39.
11. Tryggvason K, Pettersson E. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med. 2003;254:216-24.
12. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focalsegmental glomerulosclerosis: a long-term follow-up. Clin Nephrol. 1995;43:84-8.
13. Tune BM, Lieberman E, Mendoza SA. Steroid resistant focal segmental glomerulosclerosis; a treatable disease. Pediatr Nephrol. 1996;10:772-8.
14. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK. Intravenous pulse cyclophosphamide: a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol. 1994;8:1-3.
15. Tarshish P, Tobin JN, Bernstein J, Edelman CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: a report of the International Study of Kidney Diseases in Children. Pediatr Nephrol. 1996;10:590-3.
16. Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN. Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2003;18:351-6.
17. Mantan M, Sriram CS, Hari P, Dinda A, Bagga A. Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2008; 23:1495-1502.
18. Rennert WP, Kala UK, Jacobs D, Goetsch S, Verhaart S. Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol. 1999;13:113-6.
19. Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W. Cyclosporin A is superior to cyclophosphamide in children with steroid resistant nephrotic syndrome—a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol. 2008;23:1483–93.
20. Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:45-50.
21. Yi Z, Li Z, Wu XC, He QN, Dang XQ, He XJ. Effect of fosinopril in children with steroid-resistant idiopathic nephritic syndrome. Pediatr Nephrol. 2006;21:967-72.
22. Pudjiastuti P. Kadar TGF-β1 urin pada berbagai keadaan proteinuria dan efek penambahan losartan pada lisinopril terhadap kadar TGF-β1 urin pada anak dengan sindrom nefrotik resisten steroid: suatu uji klinis acak terkontrol [unpublished dissertation]. Jakarta: University of Indonesia; 2007.